Autologous cultured chondrocytes on porcine collagen membrane
Other namesMACI
Specialtyorthopedic
Autologous cultured chondrocytes on porcine collagen membrane
Clinical data
Trade namesMaci
License data
ATC code
  • none
Legal status
Legal status
Identifiers
DrugBank
UNII

Autologous cultured chondrocytes on porcine collagen membrane (Maci) is a treatment to correct cartilage defects in the knee.[1] It is used to treat symptomatic, full-thickness cartilage defects of the knee with or without bone involvement.[2][1] Autologous cultured chondrocytes on porcine collagen membrane is an autologous cellularized scaffold product.[1] This treatment is approved by the US Food and Drug Administration (FDA).[1] It is only administered to adults.[1] Healthy cartilage is removed from the person's own knees and a 'scaffold' is created on which the healthy tissue growths.[1] This is an autologous matrix-induced chondrogenesis procedure which prevents tissue rejection complications since the transplanted cartilage comes from the same person.[3]

Autologous cultured chondrocytes on porcine collagen membrane was approved for use in the United States in May 2019.[2]

See also

References

  1. 1 2 3 4 5 6 7 "Maci- autologous cultured chondrocytes implant". DailyMed. 23 October 2019. Retrieved 1 April 2020.
  2. 1 2 3 "Maci (Autologous Cultured Chondrocytes on a Porcine Collagen Membrane)". U.S. Food and Drug Administration (FDA). Retrieved 13 May 2017. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ↑ Megan B (December 14, 2016). "FDA Clears Novel Scaffold for Knee Cartilage Repair". Medscape. Retrieved 13 May 2017.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.